Glaxo Plans Changes to Compensation Program for U.S. Sales Team
This article is for subscribers only.
GlaxoSmithKline Plc, which replaced the head of its struggling U.S. operations in February, is considering changes to its compensation model for sales staff, according to an internal memo obtained by Bloomberg News.
A task force is looking at “more comprehensive options to simplify the Patient First program” for incentive pay and will provide a report within a month, London-based Glaxo said in an April 1 statement to its U.S. sales employees. Sarah Alspach, a spokeswoman for the U.K.’s largest drugmaker, confirmed the contents of the memo.